Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Caplin Point Laboratories Limited

Market Cap 190B 2.02B 1.76B 1.63B 1.53B 2.86B 2.88B 19.34B 7.5B 93.77B 7.58B 7.42B 326B P/E 2026
17.9x
P/E 2027 * 26.7x
Enterprise Value 190B 2.02B 1.76B 1.63B 1.53B 2.86B 2.88B 19.34B 7.5B 93.77B 7.58B 7.42B 326B EV / Sales 2026
5.23x
EV / Sales 2027 * 7.66x
Free-Float
26.39%
Yield 2026 *
-
Yield 2027 * 0.16%
1 day+6.11%
1 week+3.97%
Current month+23.66%
1 month+24.14%
3 months+56.07%
6 months+29.92%
Current year+36.20%
1 week 2,325.4
Extreme 2325.4
2,560
1 month 1,950
Extreme 1950
2,560
Current year 1,500.3
Extreme 1500.3
2,560
1 year 1,500.3
Extreme 1500.3
2,560
3 years 781.85
Extreme 781.85
2,641
5 years 575
Extreme 575
2,641
10 years 176.2
Extreme 176.2
2,641
Manager TitleAgeSince
Chief Executive Officer 71 2015-03-27
Director of Finance/CFO - 2016-02-18
Chief Administrative Officer - -
Director TitleAgeSince
Director/Board Member - 2026-01-30
Chairman 73 2010-01-26
Director/Board Member - 2025-11-04
Change 5-day change 1-year change 3-year change Capi.($)
+6.11%+3.97% - - 2.02B
+0.74%+1.69%+10.40%+85.32% 46.74B
-2.91%+3.09%+50.06%+90.35% 34.33B
-0.27%-2.71%-9.86%+33.69% 11.57B
-0.34%-3.07%+11.88%+92.57% 11.42B
-0.57%+0.96%+37.43%+128.26% 9.09B
+0.43%-1.68%+13.22%+41.07% 6.98B
-1.23%+1.65%+44.63%-18.54% 6.55B
+2.77%+1.83%+35.25%+243.81% 6.62B
+0.73%-2.94%-35.25%-2.32% 5B
Average +0.55%+0.08%+17.53%+77.13% 15.37B
Weighted average by Cap. -0.34%+0.99%+21.75%+82.93%

Financials

2026 2027 *
Net sales 21.28B 226M 197M 182M 170M 320M 322M 2.16B 837M 10.47B 847M 828M 36.37B 24.88B 264M 230M 213M 199M 374M 376M 2.53B 979M 12.25B 990M 969M 42.52B
Net income 6.16B 65.3M 56.94M 52.73M 49.37M 92.58M 93.14M 626M 242M 3.03B 245M 240M 10.53B 7.13B 75.54M 65.86M 61M 57.1M 107M 108M 724M 280M 3.51B 284M 277M 12.18B
Net Debt - -
Logo Caplin Point Laboratories Limited
Caplin Point Laboratories Limited is an India-based pharmaceutical company with a business model catering predominantly to emerging markets of Latin America and Africa. The Company has also entered regulated markets such as the United States through its Subsidiary, Caplin Steriles Limited. The Company's operations include research & development and manufacturing of finished formulations, active pharmaceutical ingredients (APIs), clinical research, front-end generic presence in Latin America, brand marketing in Francophone Africa and a USFDA/EU-GMP approved injectable facility. In the Regulated Markets, its products include liquid & lyophilized vials, pre-filled syringes, three-pc ophthalmic droppers and pre-mix bags. In the Emerging Markets, its products include tablets, dry syrups - bottles, soft gels, capsules, suppositories, liquid syrups - bottles, liquid injectables in ampoules & vials, lyophilized vials, prefilled syringes (PFS), and emulsion injection in ampoules & vials.
Employees
3,966
Date Price Change Volume
26-06-19 2,503.50 +6.11% 402,481
26-06-18 2,359.40 +1.05% 56,125
26-06-17 2,334.90 -1.80% 66,318
26-06-16 2,377.80 +0.56% 101,405
26-06-15 2,364.60 -1.79% 146,915
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2,506.15INR
Average target price
2,505.00INR
Spread / Average Target
-0.05%

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!